CTLA4 and neoplasm: However, tumor-bearing mice treated with a combination of HMGN1, R848, and systemic administration of both anti-CTLA4 and anti-PD-L1 together manifested significant loss of body weight (>20%) and patchy hair/hair color (data not shown), suggesting that simultaneous usage of anti-CTLA4 and anti-PD-L1 poses increased risk of unleashing autoimmune response(s).